HydroxyTyrosol / NRF2 Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱

Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).

Hydroxytyrosol is potent against CSC phenotypes. Mechanisms: -Blocks EMT, reducing transition into CSC-like states -Inhibits Notch signaling -Reduces CD44+ / CD24– CSC markers -Inhibits hypoxia-driven stemness (HIF-1α suppression) Hydroxytyrosol is especially active in: -Breast CSCs -Melanoma CSC-like cells -Gastric CSC models

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation

1 ROS tone / lipid peroxidation ↓ (low–mod dose); ↑ (high concentration only) ↓ P→R Antioxidant; membrane protection Catechol scavenger; at higher concentrations may induce pro-oxidant stress in tumors (model-dependent).

2 NRF2 axis ↑ (context-dependent) ↑ R→G Endogenous antioxidant induction ↑ HO-1/NQO1; protective in normal tissues; could support tumor stress resistance (context-dependent).

3 NF-κB / COX-2 inflammation ↓ ↓ R→G Anti-inflammatory Reduces pro-tumor inflammatory signaling; consistent with Mediterranean diet data.

4 Mitochondrial function ↔ / ↓ proliferation (model-dependent) ↑ (protective) R→G Bioenergetic stabilization Reported support of mitochondrial integrity in normal cells; may impair cancer cell proliferation via metabolic stress.

5 Apoptosis (caspase activation) ↑ (high concentration only) ↔ / ↓ R→G Pro-apoptotic in select tumors Observed at supra-physiologic exposures in vitro.

6 Ferroptosis axis ↓ (anti-lipid-ROS bias) ↓ P→R Inhibits lipid oxidation Strong antioxidant property may counter ferroptotic strategies (context-dependent).

7 Clinical Translation Constraint — — — Exposure limitations Rapid metabolism; plasma free HT lower than many in-vitro doses; best considered dietary adjunct.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation

1 EMT (Epithelial–Mesenchymal Transition) ↓ (model-/dose-dependent) ↔ R→G Reduces EMT-associated transcription (e.g., Snail, Twist) Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.

2 CSC markers (CD44⁺/CD24^–) ↓ (model-dependent) ↔ G Reduces stemness-associated phenotype Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.

3 Notch signaling ↓ (model-dependent) ↔ R→G Stemness pathway inhibition Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.

4 HIF-1α / hypoxia-driven stemness ↓ (preclinical) ↔ R→G Suppresses hypoxia adaptation Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.

5 Tumor-type specificity Breast, Melanoma, Gastric (preclinical) — — CSC-like cell sensitivity Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation

1 Lipid peroxidation / neuronal membrane protection ↓ P Neuroprotective antioxidant Protects against oxidative membrane injury; aligns with AD oxidative stress hypothesis.

2 NRF2 activation ↑ R→G Endogenous antioxidant upregulation Supports neuronal resilience under oxidative stress.

3 Neuroinflammation (NF-κB) ↓ R→G Microglial modulation Reduces pro-inflammatory cytokines in models.

4 Mitochondrial integrity ↑ R→G Bioenergetic stabilization Improves mitochondrial function in neuronal models; may reduce apoptotic susceptibility.

5 Aβ toxicity modulation ↓ (preclinical) G Reduces amyloid-induced oxidative injury Animal/cell evidence; limited direct human AD trials.

6 Clinical Translation Constraint — — Dietary-level evidence Human data strongest for Mediterranean diet patterns; isolated HT supplementation lacks large AD RCTs.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱

Source: TCGA

Type: Antiapoptotic

Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱

4641-

HT,

Hydroxytyrosol induced ferroptosis through Nrf2 signaling pathway in colorectal cancer cells

in-vitro,

CRC,

HCT116

in-vitro,

CRC,

SW48

Ferroptosis↑, Iron↑, lipid-P↑, ROS↑, GSH↓, MMP↓, GPx4↓, TLR1↑, eff↓, NRF2↓, ROS↑,

4643-

OLE,

HT,

Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine

Review,

Var,

TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Catalase↑, 1, GSH↑, 1, MDA↓, 1, NRF2↑, 1, ROS↓, 1, SOD↑, 1,

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,

Functional Outcomes ⓘ

chemoP↑, 1,
Total Targets: 8

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:226  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

HydroxyTyrosol / NRF2 Cancer Research Results

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Protein Folding & ER Stress ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Immune & Inflammatory Signaling ⓘ

Functional Outcomes ⓘ

Home Page